कंपनी का अवलोकन
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines globally to treat various diseases, with a specific focus on developing product candidates for eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases. The company operates within the Healthcare sector and the Biotechnology industry, positioning itself as a specialized entity focused on pharmaceutical innovation rather than broad consumer goods or services. This biotechnology firm maintains a substantial scale, evidenced by a market capitalization of $81.99B, annual revenue of $14.34B, and a workforce comprising 15410 employees. These valuation and revenue figures indicate that Regeneron is a large-cap enterprise with significant market penetration, suggesting a mature operational structure capable of sustaining high R&D expenditures and commercialization efforts required for biotechnology development.
वित्तीय स्वास्थ्य
The company reported revenue of $14.34B, net income of $4.50B, and EBITDA of $4.25B during the trailing twelve months, highlighting a robust operational performance. The gap between revenue and net income reveals a highly efficient cost structure, where the company converts a significant portion of its top-line sales into actual profit, indicative of strong pricing power or low cost of goods sold relative to revenue. Free cash flow stands at $3.26B, which provides the company with substantial financial flexibility to fund research and development, acquire other entities, or manage capital allocation without immediate reliance on external financing. The gross margin is 44.6%, while the operating margin is 23.1% and the profit margin reaches 31.4%, indicating that the company retains more than a third of its revenue as bottom-line profit after all expenses are accounted for. In terms of leverage, the company holds $8.61B in cash against $2.97B in debt, resulting in a debt-to-equity ratio of 9.51, which suggests a balance sheet that is conservatively managed with ample liquidity to cover obligations. The current ratio is 4.13, indicating a very strong short-term liquidity position where current assets are more than four times the value of current liabilities. Furthermore, the Return on Equity is 14.9% and the Return on Assets is 5.9%, metrics that reveal management is effectively utilizing shareholder capital and total assets to generate profitable returns.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is 18.69, while the forward P/E is projected at 14.74, implying that the market expects earnings growth in the future that would justify a lower valuation multiple compared to current performance. The price-to-book ratio stands at 2.55, indicating that the market values the company at a premium of 2.55 times its book value, reflecting the high intangible value of its intellectual property and pipeline assets. Alternative valuation metrics such as the price-to-sales ratio of 5.72 and the EV/EBITDA of 17.42 suggest that investors are willing to pay a significant multiple for sales and earnings, typical for high-growth biotechnology firms with strong revenue visibility. The stock has traded between a 52-week low of $476.49 and a 52-week high of $821.11, providing a clear range for analyzing recent price action and volatility. The beta value is 0.40, which indicates that the stock price is significantly less volatile than the broader market, moving with roughly 40% of the intensity of the overall index.
Growth & Income
Revenue growth year-over-year is 2.5%, while earnings growth year-over-year is -2.6%, indicating that earnings are currently growing slower than revenue, which may reflect one-time costs, restructuring charges, or the natural lag in translating revenue into net income due to non-recurring expenses. The company pays a dividend yield of 0.5% with a payout ratio of 8.5%, suggesting that the dividend is highly sustainable given the low payout relative to earnings and the strong cash generation capabilities. With such a low payout ratio, the company retains the majority of its earnings to reinvest into research, development, and commercial expansion rather than distributing them entirely to shareholders. Overall, the growth and income profile of Regeneron Pharmaceuticals, Inc. is characterized by stable revenue expansion, a highly sustainable dividend policy, and a valuation that reflects expectations of future earnings improvement rather than current contraction.